Genetic mutation test kit EGFR XL StripAssay
for pharmacogeneticsfor lung cancerfor genotyping

genetic mutation test kit
genetic mutation test kit
genetic mutation test kit
Add to favorites
Compare this product


for lung cancer, for genetic mutations, for genotyping, for pharmacogenetics
Tested parameter
for genes
Sample type
FFPE tissues
Analysis mode
lateral flow, enzymatic, for PCR, DNA analysis


Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancers. Somatic mutations in the epidermal growth factor receptor tyrosine kinase (EGFR-TK) domain influence the treatment with EGFR-TK inhibitors. First-line TK inhibitors, such as erlotinib and gefitinib, are effective anti-cancer drugs in NSCLC patients carrying activating EGFR mutations. Conversely, patients carrying the resistance mutation T790M do not benefit from first-line EGFR-TK inhibitor therapy. Identification of EGFR mutations allows the decision whether an EGFR-TK inhibitor is suitable for use in NSCLC therapy.
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.